HOXA9 and central nervous system cancer: Nevertheless, it is noteworthy that miR-647, miR-767-3p, and miR-935 reportedly suppress the progression of glioma through multiple regulatory axes, including miR-647/HOXA9, miR-935/FZD6, miR-935/HIF1 α, or miR-767-3p itself, making them promising biomarkers and therapeutic targets for glioma.